Carbohydrate Elimination or Adaptation Diet for Symptoms of Intestinal Discomfort in IBD: Rationales for “Gibsons' Conundrum” by Fung, Q. Manyan & Szilagyi, Andrew
Hindawi Publishing Corporation
International Journal of Inﬂammation




for Symptoms of Intestinal Discomfort in IBD: Rationales
for “Gibsons’ Conundrum”
Q. ManyanFungandAndrewSzilagyi
Division of Gastroenterology, Department of Medicine, Jewish General Hospital, McGill University School of Medicine,
3755 Cˆ ote-Sainte-Catherine Road, Room E110, Montreal, QC, Canada H3T 1E2
Correspondence should be addressed to Andrew Szilagyi, aszilagy@gas.jgh.mcgill.ca
Received 15 September 2011; Revised 13 November 2011; Accepted 14 November 2011
Academic Editor: David Sachar
Copyright © 2012 Q. M. Fung and A. Szilagyi. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Therapeutic use of carbohydrates in inﬂammatory bowel diseases (IBDs) is discussed from two theoretical, apparent diametrically
opposite perspectives: regular ingestion of prebiotics or withdrawal of virtually all carbohydrate components. Pathogenesis of IBD
is discussed connecting microbial ﬂora, host immunity, and genetic interactions. The best studied genetic example, NOD2 in
Crohn’s disease, is highlighted as a model which encompasses these interactions and has been shown to depend on butyrate for
normal function. The role of these opposing concepts in management of irritable bowel syndrome (IBS) is contrasted with what
is known in IBD. The conclusion reached is that, while both approaches may alleviate symptoms in both IBS and IBD, there is
insuﬃcient data yet to determine whether both approaches lead to equivalent bacterial eﬀects in mollifying the immune system.
This is particularly relevant in IBD. As such, caution is urged to use long-term carbohydrate withdrawal in IBD in remission to
control IBS-like symptoms.
1.Introduction
A conundrum is deﬁned by the American Heritage Dic-
tionary of the English language [1] as “a riddle, especially
one whose answer makes a play on words or as a puzzling
question or problem.” In 1995, Gibson and Roberfroid pub-
lished their treatise on the potential beneﬁts of maldigested
carbohydrates on host health through manipulation of
microﬂora [2]. The concept of prebiotics (nondigestible,
highly fermentable, dietary substances that exhibit beneﬁcial
functionsinthehostbyfacilitatingthegrowthandmetabolic
activity of either one or a selective number of health-
promoting colonic species) coincided with the emergence of
potential human beneﬁts found in probiotics (live bacteria
bypassing the acid environment of the stomach and confer-
ring health beneﬁts to the host. A combination of pre- and
probiotics is referred to as a synbiotic). A deluge of basic and
clinical studies ensued as well, on the eﬀects of prebiotics on
an array of diseases. In particular, Crohn’s disease (CD) and
idiopathiculcerativecolitis(UC)(thetwoclinicalsubtypesof
IBD) were targeted to capitalize on the potential therapeutic
eﬀects of either pro- or prebiotics [3–5] .W h i l eC Da n d
idiopathic UC both share somewhat similar epidemiology
and are thought to have originated from common genetic
and environmental etiogenesis, they are in fact considered as
two diﬀerent entities. CD is unrestricted to any part of the
gastrointestinal tract, in which the terminal ileum with or
without the proximal colon remains the most common site
aﬀected.InUC,pathologytendstobegininthedistalrectum
and then it may proceed to involve the rest of the colon in a
uniform fashion.
Similarly a benign but lifestyle-altering condition of
irritable bowel syndrome (IBS—a chronic functional bowel
disorder encompassed by frequent recurrences of abdominal
pain is associated with altered bowel movements: diarrhea,
constipation, or alternating form) also fell into the category
potentially amelioratedbyprobiotics andperhapsprebiotics.




Figure 1: This Venn diagram shows the relationship between
FODMAP, comprises of fructose, oligosaccharides, disaccharides,
monosaccharides, and polyols. The central diet includes the major-
ity of carbohydrates which are hypothesized to be malfermented by
lower intestinal bacteria and therefore leading to excess production
of gas and short-chain fatty acids with induction of symptoms.
Thus, FODMAP includes all prebiotics in which lactose is included
also as a restricted probiotic in lactose maldigesters. It is the
hypothetical beneﬁts of either withdrawal from diet or adapting
to the prebiotic components of this diet that potentially forms a
scientiﬁc conundrum in application.
that bacterial interactions, abnormal fermentation, and host
handling of fermentative products as well as an immune
response rather contributed to aggravation of symptoms
[6, 7]. In 2005, Gibson and Shepherd hypothesized such
mechanisms in causation of gastrointestinal symptoms in
these disorders and suggested that carbohydrates be with-
drawn from diets of symptomatic IBS or IBD patients.
This FODMAP diet suggests the withdrawal of fermentable
oligo-, di-, monosaccharides, and polyols from the diet
[8]. As such, the FODMAP diet includes lactose and most
other prebiotics (refer to Figure 1 and Table 1). Some of
theserecommendations,ofcarefulcarbohydrateselectionfor
diet in patients with IBD, were also suggested earlier in a
book by Gottschall [9]. There was less emphasis on small
molecules except for sweeteners and more on large complex
carbohydrates.
The presentation of these two hypotheses, then, for-
mulates a conundrum. In the ﬁrst instance, carbohydrates
bypassing absorption in the small intestine can speciﬁcally
manipulate metabolism and beneﬁt the commensal bacteria,
which in turn help reduce inﬂammation. It is important
to note that there are speciﬁc recognized prebiotics, but all
carbohydrates interact with the microbiome. In the second
scenario, a wide array of carbohydrates, including prebiotics,
are withdrawn. Are the end results equivalent, that is,
has a stimulated immune system been placated? A similar
paradigm applies to use of probiotics [10] or antibiotics
w h i c hh a v er e c e i v e ds o m es u c c e s sb o t hi nI B D[ 11]a n d
IBS [12–14] as well as to other dietetic interventions. These
include enteral/polymeric diets and nonspeciﬁc exclusion
dietsthathavepreviouslybeenimplicatedfortheirtherapeu-
tic roles which are beyond the scope of this review [15].
Herein we will focus on discussing the rationales behind
theusageornonusageofFODMAPdietinIBD.EﬀectsinIBS
will be discussed overall, but the concept will be discussed
in detail as it might apply to IBD based on current concepts
of pathogenesis. The objectives are to review carbohydrate
pathogenic interactions with intestinal immunity and to
conceive an eﬀective intervention that convenes the apparent
hypothetical contradictions inherent in the two approaches
to carbohydrate use.
2. MicrobialDiversityin the Gut
2.1. Normal Development. The gastrointestinal microbiota
(or microﬂora) diﬀers among individuals and its dominant
bacterial phylotypes are acquired from the moment of birth.
Although intestinal microbial composition will remain fairly
constant from early infancy throughout adulthood once
bacterial colonization is established [16], these microorgan-
isms respond adaptively to better accommodate and protect
at an individual level. As such, fecal samples adequately
reﬂect the colonic bacterial environment and indicate the
individual’s intestinal status in response to developmental
changes, environmental factors, antibiotic usage, or illness.
The recent advancement in molecular proﬁling methods,
such as high-throughput sequencing of microbial 16S ribo-
somal RNA genes [17] and metagenomics [18], provides
a comprehensive insight into the 100 trillion bacteria that
currently comprise the microbiota in the distal gastroin-
testinal tract alone. Representing the two predominant
phylotypes found in mucosal and luminal microbiota are
Gram-positive Firmicutes (species including Clostridia and
Lactobacillaceae) and Gram-negative Bacteroidetes (species
including Bacteroides), all of which are obligatory anaerobic
bacteria.
2.2. Functions of the Microbiome. Sharing a symbiotic rela-
tionship with a dynamic bacterial community also means
acquiring a diverse metabolic proﬁle essential for intestinal
development [19]. The resident microﬂora promotes the
diﬀerentiation and proliferation of enteric epithelial cells
by harvesting essential minerals (e.g., iron, calcium, and
magnesium) as well as mediating the synthesis of vitamins
(e.g., cobalamin, vitamin K, biotin, pyridoxal phosphate,
and tetrahydrofolate). In addition, the bacterial genome
(also known as the microbiome) encodes a large repertoire
of saccharolytic enzymes, including glycoside hydrolases
and polysaccharide lyases, needed to further metabolize
nondigestible carbohydrates such as plant polysaccharides
(dietary ﬁbers), oligosaccharides, lactose (especially in lac-
tose maldigesters), and sugar alcohols in the proximal colon
through a process called saccharolytic fermentation [18].
This colonic fermentation of macronutrients yields various
end products like gaseous compounds (e.g., hydrogen gas,
methane, and carbon dioxide) and short-chain fatty acids
(SCFAs), with the latter being mostly comprised of acetate,
propionate, and butyrate. These are utilized as the primary
energy source for the colonic mucosa. Colonic concentration
of SCFA substrates is determined not only by the consump-
tion of dietary ﬁber but also by the bacterial species present
in the microbiota. For example, the two prominent bacterialInternational Journal of Inﬂammation 3
Table 1: List of poorly digested carbohydrates comprised of FODMAP and select prebiotics (∗), as well as their respective sources. This is
not a complete list, and other complex carbohydrates which have eﬀects on bacteria are also included in FODMAP.
Molecular form Common sources
Inulin (∗) Onions, leeks, chicory, artichoke, wheat, banana
Oligofructose (∗) Hydrolysis product of inulin
Short-chain fructo-oligosaccharide (∗) Hydrolysis product of inulin
Trans galacto-oligosaccharides (∗) Manufactured from lactose
Lactulose (∗) Manufactured from lactose
Fructo-oligosaccharides (∗) May be present in breast milk, formed from lactose
Isomalto-oligosaccharides (∗) Present in foods, potential prebiotic
Lactose (∗) Present in dairy products made from animal sources, prebiotic mostly in lactose maldigesters
Polyols Sugar alcohols (sorbitol, mannitol, xylitol, maltitol, and isomalt), cauliﬂower, avocado, mushrooms
phylotypes each diﬀers in the types of SCFAs produced, with
Firmicutes selectively producing butyrate and Bacteroidetes
controlling the levels of acetate and propionate production
[20, 21]. Small carbohydrates like lactose may also lead to
production of butyrate through the stimulation of second
tier bacteria (butyrogens) by initial breakdown products
[22, 23]. The presence of these organic acids helps induce
an acidic environment unfavourable for the proliferation
of strict anaerobic species [24, 25]. Once carbohydrates are
no longer available for fermentation, bacteria will proceed
to proteolytic fermentation (less favourable) in the distal
colon where proteins derived from diet, endogenous cellular
proteins, and bacterial cells are catalyzed to toxic, car-
cinogenic metabolites (e.g., bacteriocins, ammonia, indoles,
and phenols) [26]. These substances inhibit the growth
or kill potentially pathogenic constituents. Another way
the microbiota maintains resistance against colonization
by pathogenic organisms is to compete for nutrients and
attachment sites to the mucosal surface in the colon [27, 28].
Minor perturbations in the intricate microbial diversity can
have signiﬁcant impact on the gut homeostatic balance [29–
32]. These changes have been implicated to predispose or
contribute to conditions such as sepsis, IBS symptoms [6,
33], and even obesity in some populations [34, 35].
3. The Interaction of the Microbiome with
IntestinalMucosal Immunity
3.1. Mucosal Immune System. Intestinal mucosal immunity
is associated with the integrity of the intracellular junctions
in the gut epithelium constituting what is called a physical
barrier. The mucosal integrity is further strengthened by
whatiscalledachemicalbarrierthankstoaspecializedgroup
of diﬀerentiated epithelial cells residing in the paracellular
space. Goblet cells, for instance, are responsible for secreting
an overlying glycocalyx layer composed of mucin glycopro-
teins [36]; production of defensins, immunoglobulins, and
other substances by enterocytes, lymphocytes, and Paneth
cells (the last being generally restricted to the crypts of
Lieberkuhn in the distal small bowel) can also be found
within this mucus layer [37, 38]. This dual barrier provides
enhanced protection against unwarranted entry of luminal
contents (including self- and non-self-antigens) into the
systemic immune system, but this is also where innate
immune recognition takes place. Many of the cells in
this mucosal barrier respond to pathogens by expressing
two functionally important subsets of pattern-recognition
receptors (PRRs)—extracellular Toll-like receptors (TLRs)
and intracellular nuclear oligomerization domain-(NOD-)
like receptors. These assist in the detection of pathogen-
associated molecular patterns (PAMPs) through the leucine-
rich repetitive (LRR) domain. Lipopolysaccharides (LPSs)
andpeptidoglycan(PGN)components(i.e.,muramyldipep-
tide) of bacterial cell wall are two examples of PAMPs.
Each subset can either individually or convergently activate
nuclear factor κB( N F - κB) eﬀector in the defense against
foreign pathogens by producing inﬂammatory cytokines
(e.g., TNF-α and IL-1β) and antimicrobial peptides [39].
Chronic stimulation of PRRs by PGN can also produce
inhibitory cytokines (e.g., TGF-β and IL-10) via the NOD2-
dependent pathways to minimize excessive tissue injury
induced by intestinal antigen-presenting cells [40]. Intestinal
mucosal immunity is reinforced further by continuous
interaction between epithelial cells and adaptive immune
cells, including eﬀector T-helper cells (Th1, Th2, and Th17),
regulatory T cells (Foxp3+ Treg), and other immune cells
(i.e., dendritic cell, macrophage, and natural killer cell) at
the follicle-associated epithelium junction overlying the gut-
associated lymphoid tissue [41].
Central to the discussion in conferring protection to
the host is the inﬂuences of microbiota community on the
normal development and homeostasis of mucosal immunity
[52–54]. The symbiotic nature of the host-microbiota rela-
tionship is fundamental to the shaping of immunological
function, balance, and tolerance in the gut. Paradoxically,
the key for preserving such symbiotic coexistence in return
dependsontherobustnessoftheintestinalimmunenetwork,
particularly in its ability to diﬀerentiate between symbi-
otic and pathogenic colonization. The maintenance of gut
homeostatic balance, therefore, depends on the cooperation
between mucosal immunity and microbial community, that
is, if the right microbiota composition is present. Alteration
to the microbial ecology, commonly referred to as dysbiosis,
can distort intestinal immune responses by shifting the
equilibrium between pro- and anti-inﬂammatory T-helper
cells diﬀerentiation, as characterized by IBD pathogenesis
(Box 1)[ 55–57].4 International Journal of Inﬂammation
Classically, IBD (especially in CD) is associated with a hyperactive innate immune response
producing unrestrained levels of proinﬂammatory cytokines and chemokines (e.g., IL-12, IFN-
γ,a n dT N F - α), resulting in a marked expansion of lamina propria. This propagates further
inﬂammation by recruiting T-helper 1 (CD4+ T h 1 )c e l l s .A l t e r n a t i v e l y ,t h eo p p o s i t es c e n a r i oc a n
occur in which resident tissue macrophages fail in their attempt to initiate an innate immune
response against foreign antigens and are defective in the secretion of proinﬂammatory
cytokines [42, 43]. Reduced concentrations of these mediators mean neutrophil recruitment
cannot be adequately enforced at the lamina propria, resulting in impaired clearance of antigenic
contents [44]. The following overcompensatory immune responses lead to either a polarization
toward an atypical humoral phenotype driven by T-helper 2 (CD4+ Th2) cells along with
mediators such as IL-4 and IL-13 (especially in UC [45]) or recruitment of CD4+ Th1 cells
[36]. The ampliﬁcation of inﬂammatory response as an attempt to remove foreign material only
incites further epithelial injury which coincides with a decreased production of defensins [46, 47].
It is quite possible that both paradigms may be true given the genetic heterogeneity among
IBD populations. A newly discovered subset of inﬂammatory T cells, known as T-helper 17
(Th17) cells, produces the proinﬂammatory cytokine IL-17 and requires IL-23 for proper
maintenance and function. Indirectly, Th17 cells relate CD and UC etiologies due to IL-23
sharing similar subunits with another major cytokine found in the Th1 phenotype, namely, IL-12
[48, 49]. Also, responsiveness to anti-TNF-α treatment suggests common pathogenic pathways
are shared by both IBD subtypes [50, 51].
Box 1: IBD pathogenesis.
3.2. Concept of Dysbiosis and IBD. Analyses in the gastroin-
testinal microbial populations showed signiﬁcant diﬀerences
between healthy individuals and patients with IBD, an
indication that dysbiosis may be a contributing factor to IBD
[58, 59]. Speciﬁcally, an increased propensity of obligatory
aerobic bacteria is seen displacing the anaerobic species, with
Biﬁdobacteria (in CD) [60] and Lactobacilli (in UC) [20]
both being deﬁcient in the microbiota. Reduced diversity
of mucosa-associated phyla Firmicutes and Bacteroidetes
is commonly observed as well in IBD controls [59, 61].
Depletion of Faecalibacterium prausnitzii is related to an
activated immune response, which speciﬁcally suppresses
and eradicates selective groups of bacteria resulting in an
imbalance of intestinal ﬂora [62]. This is relevant due
to F. prausnitzii belonging to the genus Firmicutes in
the Clostridia 14 cluster, which in fact is an important
butyragenic-stimulated bacterium capable of exerting anti-
inﬂammatory eﬀects [63].
Swidsinski et al. has shown that a person aﬄicted
with IBD displays an intestinal mucosa heavily populated
with adherent organisms which are virtually nonexistent in
a healthy individual [64]. For instance, adherent-invasive
E. coli are isolated and found to adhere to the brush
border of primary ileal enterocytes of CD patients but
none in healthy controls [65–67]. Most recently, however,
Willing et al. demonstrated that speciﬁc bacterial changes
were associated with diﬀerent anatomical sites in CD but
UC patients in remission shared a similar microﬂora as
to healthy controls [68]. This correlates with the data
gathered from a comparative microbiota analysis of mice
where they found closely related phylotypes displayed higher
abundances (cooccurrence) and are conducive to intestinal
colonization irrespective of the microbial origin (external
or internal) [69]. Highly abundant subsets of commensal
microorganisms, such as Helicobacter, Clostridium,a n d
Enterococcus species,arehencemoresusceptibletotransform
thesymbioticnatureofthehost-microbiotarelationshipinto
a pathogenic one under certain environmental conditions
[54]. Mucosal antibodies recovered from IBD subjects are
found to be directed against intestinal commensal bacteria,
as such, they may be more responsive to antibiotic treatment
and faecal diversion than non-IBD controls [70, 71].
4.The Relationship of BacterialMetabolites
of CarbohydratesandMucosal Immunity
4.1. Immunoregulatory Functions of Short-Chain Fatty Acids.
Given that environmental-induced changes can alter the
intestinal microbiota, leading to dysregulatory inﬂamma-
tory responses, increasing evidence indicates that microbial
fermentative by-products (e.g., acetate, propionate, and
butyrate) demonstrate anti-inﬂammatory properties that
maybeclinicallyrelevanttothetreatmentofIBD[14,77,90–
93].Onestudyattributedtheinteractionbetweenacetateand
the chemoattractant receptor, G-protein-coupled receptor
43 (GPR43; also referred to as FFAR2) [94], critical in
the regulation as well as the resolution of inﬂammatory
responses [95]. By analyzing the transcription proﬁles of
cellular receptor genes found in human leukocytes, the
investigators had identiﬁed high degree of GPR43 expression
in neutrophils and eosinophils; its expression was also
closely governed by Toll-like receptors (TLR2 and TLR4),
formyl peptide receptors (FPR1 and FPR2), and C5aR
suggesting that GPR43 is important for innate immune and
chemoattractant-induced responses. To examine the anti-
inﬂammatory protection conferred by the acetate-GPR43
signalling pathway, they induced acute colitis by adding
dextran sulphate sodium (DSS) to the drinking water of
GPR43-deﬁcient (Gpr43−/−) and wild-type mice for oneInternational Journal of Inﬂammation 5
Table 2: Some immunoregulatory functions of butyrate.
(i) Increases choline acetyltransferase immunoreactive (ChAT-IR) enteric neurons in vivo and in
vitro
(ii) Increases cholinergic-mediated colonic motility and contractile response ex vivo
[72]
(i) Modulates oxidative stress in healthy colonic mucosa
(ii) Promotes glutathione (GSH) and lower uric acid concentrations compared [73]
(i) Promotes the diﬀerential expression of 500 genes in human colonic mucosa
(ii) Increases gene expression of transcriptional regulation pathways: fatty acid oxidation,
electron transport chain, and oxidative stress
(iii) Increases gene expression related to epithelial integrity and apoptosis
[74]
(i) Inﬂuences colonic function, mainly by histone deacetylase inhibition [75, 76]
(i) Reduces inﬂammatory responses in vitro, mainly by inhibition of NF-κBa c t i v a t i o n [ 77]
(i) Mediates NOD2-dependent mucosal immune responses against PGN [78]
(i) Modulates an intracellular JAK/STAT1 signaling cascade which inhibits NO production [79]
(i) Enhances upregulation/detection of PRRs on intestinal epithelial cells [80–83]
(i) Anticarcinogenic/angiogenic by modulating the activity of several key regulators involved in
apoptosis and cell diﬀerentiation [84–86]
(i) Enhances colonic defense barrier [87–89]
week. Compared to the wild-type, Gpr43−/− mice exhibited
exacerbated inﬂammatory response based on histological
analysis, daily activity index (DAI; a combined measure
of weight loss, rectal bleeding, and stool consistency), and
increased levels of myeloperoxidase activity (MPO; inﬂam-
matorymediator)inthecolon.Asigniﬁcantimprovementto
those inﬂammatory parameters soon followed after 200mM
acetate was introduced in their drinking water in a GPR43-
dependent manner (Gpr43−/− mice lacked the receptor to
respond to acetate but not in wild-type ones). Similar
development of unresolved inﬂammation occurred in other
mice models such as DSS-induced colitis in germ-free wild-
type,K/BxNserum-inducedmodelofinﬂammatoryarthritis
and ovalbumin-induced model of allergic airway inﬂam-
mation. Host protection against enteropathogen Escherichia
coli (0157:H7) infection was recently linked to acetate
production by Biﬁdobacteria [96]. They proposed that
acetate prevented the pathogen from entering the systemic
circulation by enhancing mucosal barrier defense.
Although acetate and propionate have long been shown
to exert immunologic modiﬁcation [14], it is butyrate
which generates the majority of interest in research. The
immunoregulatory activities exerted by butyrate are listed in
Table 2.B utyrat eisablet or egulat em ultiplegenee xpr essions
in the colonic epithelial cells [74, 75]. Inhibition of histone
deacetylase by butyrate has been identiﬁed to orchestrate a
series of downstream eﬀectors responsible for its attributive
anti-inﬂammatory proﬁle [76, 97]. Most notably is the
direct suppression of the NF-κB transcription factor via
histone acetylation, which in turn alters the transcriptional
patterns of many genes encoding cytokines, chemokines,
adhesion molecules, and other proinﬂammatory mediators
[77, 98–101].
Other anti-inﬂammatory properties of butyrate high-
lighted as possible therapeutic targets in IBD include its
ability to modulate an intracellular JAK/STAT1 signalling
cascade which reduces NO production in macrophages
and in intestinal myoﬁbroblasts [79]; enhance the upreg-
ulation/detection of PRRs on intestinal epithelial cells
(e.g., TLR1, TLR4, TLR6, peroxisome proliferator-activated
receptor-γ (PPARγ)) [80–83], hence facilitating the migra-
tion of neutrophil [102]; mitigate the extent of DNA damage
in colonocytes induced by neutrophilic oxidizing species
during carcinogenesis [103, 104]; potentiate the expression
of heat shock proteins, especially HSP70 and HSP25, in
enterocyte-like Caco-2 cells and DSS-induced colitis which
further enhances cellular protection during an inﬂammatory
response [105, 106].
In some cultured cell lines, butyrate improved the status
of intestinal defense mechanisms commonly impaired in
IBD by restoring mucosal barrier integrity and promoting
epithelial migration in a dose-dependent manner [87–89].
Speciﬁcally, its administration has been demonstrated to
stimulate MUC2 mucin gene expression in which its protein
product is often altered in IBD [107–109]. An increased
mucin secretion has also been reported in the isolated
vascularly perfused rat colon [110]. Butyrate was also
demonstrated to modulate the expression of antimicrobial
peptide, cathelicidin (LL-37), in isolated colon epithelial cell
lines [111]. A reinforced mucus layer and epithelial tight
junctions mean decreasing mucosal permeability, making
foreign substances impossible to pass through the defense
barrier.
Todatepotentialtherapeuticeﬀectsofbutyratehavebeen
limited to UC. Interestingly, in vivo studies have shown that
butyrate oxidation in the colon mucosa of patients with
quiescent UC remain normal, whereas those with an actively
inﬂamed mucosa do not [112]. It was reported that TNF-
α, an inﬂammatory mediator, may be responsible for the
reduced colonic uptake of butyrate [113]. The deprivation of
butyrate or any other SCFAs, in conjunction with the toxic
metabolites derived from proteolytic fermentation when
saccharolytic fermentation is not possible, has long been
proposed for the pathogenesis of gastrointestinal disorders6 International Journal of Inﬂammation
(or even cancer) identiﬁed to originate in the distal colon
[114]. Similar proposal concerning their therapeutic role in
the regulation of inﬂammatory immune responses and the
defense of mucosal immunity with respect to cellular func-
tionsinthecolonisalsomade[26,115–117].Thetherapeutic
eﬀects of either butyrate alone or combination of SCFAs on
patients with moderate-to-active colonic inﬂammation were
conﬁrmed. Many of the UC patients showed responsiveness
toward rectal enema treatment of butyrate (amid method-
ological and procedural diﬀerences), whereby symptomatic
improvement was reported afterward and coincided with a
reduction in the inﬂammatory parameters [93, 118, 119].
Despite the fact that clinical data have not established an
eﬃcaciousdietaryquantity/frequencyofbutyrate[120–122],
current in vitro and ex vivo studies do implicate a regulatory
role in intestinal mucosal immunity.
5. GenesandIBD
Disease expression observed in individuals with IBD are a
result of genetic predisposition to mounting an inappro-
priate inﬂammatory response toward commensal microﬂora
(i.e., anergy is breached) [123, 124]. Some view immun-
odeﬁciency phenotype as the principle drive behind IBD
pathogenesis [125, 126], but external variables including
degree of bacterial load, malnutrition, surgery, and/or use
of immunosuppressant therapy must be present in order to
facilitate the disruption of the mucus layer and/or epithelial
tight junctions. As a result, rendering the submucosal com-
partments to become increasingly susceptible to bacterial
e x p o s u r e ,p e n e t r a t i o n ,a n da d h e r e n c e[ 36, 127–130]. Most
importantly, these variables predispose to abnormal inter-
actions with the microbiota. Whether observed dysbiosis,
particularly in CD, is a result of the host reaction and/or
therapy or a precursor to disease development is unclear yet.
Early progress was centered on characterizing genetic
variationsinassociationwithIBDsusceptibilityassupported
by familial aggregation studies and population-based cohort
surveys. It was suggested that geographic location, ethnic
background, socioeconomic class, and positive familial IBD
history (e.g.,ﬁrst-degree relatives and monozygotic twin) are
all variables dictating the risk in an individual for developing
IBD [131, 132]. Out of the 71 CD candidate genes and 47
for UC that have been identiﬁed to date [133], only about
30 of them are clearly delineated [50]. Genetic studies are
providingmoreconcreteevidenceforearlierepidemiological
studies, but at the same time pose additional questions that
further highlight the complex etiologies associated with IBD.
Despite some similar phenotypic traits, IBD subtypes do
not share all susceptibility loci. Another key ﬁnding reveals
that allelic variants to date confer to only a small fraction
of disease heritability in the IBD populations. This suggests
that as yet unidentiﬁed genes or other environmental factors
are attributable to IBD pathophysiological development.
Indeed in CD genetic predisposition to bacterial infections is
generally not enough to bring forth the clinical symptoms. A
number of additional environmental factors have now been
delineated, and these include smoking (promotes CD and
protects against UC) [134], appendectomy (may promote
CD and protects against UC) [135], nonsteroidal anti-
inﬂammatory drugs (promote CD) [134], bacterial or viral
infections (disrupt mucosal permeability of the intestine)
[134], and early exposure to antibiotics (promote CD) [136].
5.1. Mechanistic Model of Genetic, Nutrient, Microbial Inter-
action: Function of NOD2. The ﬁrst and most consistent
mutations associated with increased susceptibility of CD
(but not UC) are in the nucleotide-binding oligomerization
domain containing 2 (NOD2) gene located on chromosome
16q12. Formerly it was known as caspase activated recruit-
ment domain protein 15 (CARD15) gene [39]. Considerable
research has revealed a complex of interactive components
necessary for the normal function of disposing the host
of bacterial invaders. This section reviews the components,
genetic and dietary, needed for such function. It is used
primarily here as an example of the mechanistic interactive
eﬀects outlined above and how dysfunctions in diﬀerent
components could lead to disease.
Nod2 protein (product of the NOD2 gene) belongs to
the family of PRRs. Upon recognition of bacterial-associated
PGN patterns, it mediates the activation of two pathways—
NF-κB and mitogen-activated protein (MAP) kinase. This
intracellular receptor located predominantly in Paneth and
other cells situated in the distal ileum plays a key part in the
innate immune defense by eliminating intracellular bacteria
orbacterialdebris[137].Itsgeneticmutationsconfersuscep-
tibility in CD mice models [138]. Three major NOD2 muta-
tions associated with the LRR domain have been conﬁrmed:
two missense SNPs (Arg702Trp and Gly908Arg) and one
frameshift variant (Leu1007fsinsC), respectively [139–141].
All three mutations share similar restricted activation of the
NF-κB pathway in response to LPS and PGN treatments
[140, 142, 143]. Despite the prevalence of NOD2 mutations
present among the Caucasian populations (approximately
30% of patients of European ancestry have at least one of the
three polymorphisms), the genetic penetrance corresponds
to less than 10% of CD manifestation found in the carriers
[144, 145].
5.2. Genetic Components for Normal NOD2 Function. A
number of genes interact to promote normal NOD2 func-
tion. These include genes controlling Toll-like receptors,
autophagy genes (ATG16L1 and IRGM), and most recently,
products of Transducin-like enhancer of split 1 (TLE1)
also demonstrate major eﬀects. Even though loss of func-
tion/regulation in NOD2 may not compromise NF-κB
signalling completely, an imbalance of immune activity
among mucosal cells is often the case due to oversecretion
of proinﬂammatory cytokines as an attempt to dispose
bacterial components [146]. A recent paper reported that
TNF receptor 4 (TRAF4) is responsible for downregulating
the activation of NF-κB, hence limiting the innate response.
This indicates that mutations in this downregulator may be
key in correcting the acute innate response similar to how
bacterial inoculation could do for NOD2 polymorphisms
[147].International Journal of Inﬂammation 7
Autophagy is a highly conserved cellular process rec-
ognized for its role during starvation and in intracellular
pathogen clearance. In the former, intracellular components
are degraded indiscriminately to ensure cell viability. In the
latter case, the process involves the precise rearrangement
of intracellular constituents (e.g., bacteria, mitochondria,
intracellular membranes, and proteins) to form a macroau-
tophagy structure in order to isolate the foreign pathogen
for digestion. It is then sequestered in a double-membrane
cytosolic vacuole called an autophagosome which later fuses
with lysosomes for further processing [148, 149]. Genome-
wideassociation(GWA)studieshaveidentiﬁedtwosequence
variants involved in the autophagy pathway, ATG16L1 and
IRGM1, which confer to the genetic susceptibility of CD
[150–153]. Although the functional consequences as to
how ATG16L1 and IRGM1 mutations contribute to the
pathogenesis of CD are not fully understood, accumulating
humangeneticdatasuggestthatthelocationofATG16L1risk
allele on chromosome 2q37 might be linked to autophagy
mutations found in macrophage and Paneth cell.
Most recently a number of proteins have been identiﬁed
in vitro to interact with NOD2 [154]. Using a yeast 2-hybrid
screen some have been connected to a gene TLE1 which
aﬀects mucin biosynthesis and apoptosis. These epistatic
interactions are putatively regulatory, and mutations in one
of the alleles of TLE1 appear to be necessary for CD risk in
the presence of classical NOD2 mutations. This allele may
also increase the risk for UC which is independent of NOD2
mutations.
5.3. Nutrient Components for Normal NOD2 Function. In
addition to the genetically mediated controls outlined for
NOD2, two environmental variables have been shown as
requirements for normal execution of intracellular bacterial
elimination. One study by Wang et al. linked in vitro 1,25-
dihydroxyvitamin D (or vitamin D) requirement for normal
NOD2 function which was measured through the release
of stimulated NF-κB products and defensin β2[ 155]. The
presence of mutations of NOD2 could not be corrected
by increasing media levels of vitamin D. The other paper
by Leung et al. reported that, in response to the selective
modulation of histone acetylation in the NOD2 promoter
region by butyrate, an upregulation of Nod2 was observed.
The result is a dramatic enhancement in the production of
two chemokines, IL-8 and GRO-α, in the presence of PGN.
However, in its absence, butyrate only had a slight eﬀect
on IL-8 concentration without altering the NF-κB associated
IL-8 promoter region concentration levels. Their results are
in agreement with the observation made by Fusunyan and
colleagues, such that NF-κB suppression by butyrate is an
indicationthattheupregulationofIL-8mustbeindependent
of NF-κB-mediated mechanism [78, 100]. Butyrate addition
to the in vitro Caco-2 cell line enhanced PGN-mediated IL-
8a n dG R O - α production. These products also depended
on the induction of NF-κBa sw e l la sP G N[ 78]. Taken
together these two reports outline a molecular model for the
interactions between the NOD2 genetic consortium and 2
important environmental variables which impact on normal
function. To date there is no information to our knowledge
whether these 2 variables, vitamin D and butyrate, serve
redundantorsynergistic(additive)functions.Untilthattime
theroleofbutyratemaybeessentialforappropriateclearance
of intracellular bacterial products and innate immunity.
6.DietaryCarbohydrates,
Symptoms, Pathogenesis
The impact of dietary interventions for the management
of IBD has kept abreast of the scientiﬁc research outcome
in the last two to three decades, albeit that results are
less compelling than theory would suggest. Rationales for
speciﬁc interventions in particular are more deﬁned. For
example, the use of anti-inﬂammatory omega-3 fatty acids
seems rational, although outcomes are not satisfactory
[172, 173]. In the case of carbohydrates, Gibson and
Shepherd argue that distribution and subsequent rapid
fermentation of FODMAP molecules predispose the distal
small intestinal and colonic lumen to increased intestinal
permeability, an underlying factor to the development of
CD in genetically susceptible individuals [8]. They have
advocated the pathophysiological involvement of FODMAPs
in CD as a direct consequence of widespread consumption
in Western societies. Excessive exposure of high fructose
corn syrups and caloric sweeteners, commonly present in
soft drinks and various manufactured food products [174],
also appear to correlate with an increase in functional GI
symptoms.Aswell,lactosesensitivity,independentofknown
genetic lactase status, has now been conﬁrmed in patients
with CD [160].
Consumption of FODMAPs exerts osmotic eﬀects by
increasing luminal ﬂuid, inducing intestinal distension,
altering intestinal contractile patterns, and accelerating tran-
sit time [175]. Development of these symptoms leads to
the concept of global restriction of all poorly absorbed,
rapidly fermentableshort-chain carbohydrates as opposed to
selectively limiting a few food items [176–178]. FODMAPs
aggravate symptoms possibly further by inducing abnormal
motility patterns as a consequence of colonic microﬂoral
modiﬁcation to accommodate the high volume of such
consumption [163] or the incompletely evaluated role of
intestinally released gut hormones as described with the
prebiotic lactulose [179, 180].
6.1. Eﬀects of Carbohydrate Withdrawal on Microbial Flora.
Early etiological studies of IBD (especially CD) have con-
sistently suggested that high consumption of reﬁned sugar
may be an independent risk factor [181–185]. More recent
publications, however,havequestionedthis eﬀect[186–188].
Nevertheless, a possible explanation for this observation has
been provided by the proposed prebiotic concept [2]. There
are, however, little data on microbial eﬀects of complex
carbohydrate withdrawal. Rats restrictive of food for 20
weeksresultedinnonsigniﬁcantchangesinreductionoftotal
anaerobic microbes and no signiﬁcant shifts in population
species [189]. When rats were fed sucrose or starch in eq-
uicaloricamountsfor9months,noweightchangesoccurred,8 International Journal of Inﬂammation
Table 3: Comparison of putative pathogenic mechanisms in inﬂammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
IBD
(i) Genetic predisposition (extensive) [39, 131, 140, 150, 152, 156, 157]
(ii) Intestinal microﬂora alterations [55–57, 59–61, 65, 124, 158, 159]
(iii) Altered immunity (extensive) [42–44, 123, 125, 126]
(iv) Altered carbohydrate sensitivity [160]
(v) Tissue destruction and complications [50, 124]
IBS
(i) Genetic predisposition (exists but not yet worked out) [161, 162]
(ii) Microﬂora alterations especially after gastroenteritis [6, 33, 163–165]
(iii) Altered immune response (variable and mild) [166]
(iv) Altered carbohydrate sensitivity [167–170]
(v) No evidence for tissue destruction [171]
but the aerobic population increased and ratio of anaerobes
toaerobesdecreased[190].MostimportantlythetotalSCFAs
production was signiﬁcantly higher in starch than sucrose-
fed rats, although the ratios remained the same.
6.2. Eﬀects of Carbohydrate Feeding on Microbial Flora. On
the contrary there are abundant data on the eﬀects of
poorly digested carbohydrates on microﬂora. Maldigested
carbohydrates in general alter numbers [191]a n dt y p eo f
intestinal cells [192], SCFAs production, colonic pH [191,
193], and microbial numbers as well as diversity [194]. As
for prebiotics (those maldigested carbohydrates which ﬁt
more to the deﬁnitions as proposed by Gibson et al. [195]),
short-chain (oligofructose) as well as long-chain fructose
(inulin) polymers, all of which promoted the production of
SCFAs [196], Biﬁdobacteria and Lactobacilli species in stool
[197, 198], and other mucosal-associated microbial species
[199].
In the case of IBD, the introduction of fructooligosac-
charides or lactulose in healthy rats has demonstrated a
combined eﬀect of increased bacterial translocation, epithe-
lial cell proliferation, colonic epithelial injury, and mucin
production despite prebiotic consumption [200]. Among
rats fed a FODMAP-like diet in conjunction with Salmonella
species infection, severe colitis developed while only mild
colonic inﬂammation was observed in controls [200].
Furthermore, a number of other published studies
have demonstrated the protective role of both traditional
prebiotics as well as other maldigested carbohydrates against
experimentally-induced colitis (reviewed in [5]). The animal
models employed in those experiments include the IL-10-
deﬁcient and trinitrobenzene sulfonic acid (TNBS) mouse
model of CD and the DSS mouse model of UC. In these
cases lactulose, fructo-oligosaccharide, and trans-galacto-
oligosaccharide prebiotics as well as germinated barley
foodstuﬀs (derived from beer production) alter colonic
physiologyviapH,SCFAsproduction,microbialspecies,and
outcome of induced colitis.
Probiotics and prebiotics have generally been associated
with improvement in clinical IBD [201]. It is postulated that
pro- and prebiotics modulate the extent of inﬂammation
during the progressive stage of the condition. In this context
probiotics may have an advantage in UC [202], despite
beneﬁt of any speciﬁc probiotic in CD to date has not been
substantiated [203]. Prebiotics in CD have generally shown
some eﬀect but again not substantiated (see the following).
6.3. Irritable Bowel Syndrome and Inﬂammatory Bowel
Disease. An example where dietary intervention takes into
consideration both outlined concepts of carbohydrate eﬀects
is IBS. Neurological disturbances [204–207], abnormalities
in the brain-gut axis [208, 209], hyperreactivity to stress
[210], and impaired gut motility or transit [211, 212]a r e
etiological factors previously proposed to drive symptom
proﬁles of IBS. However, until recently etiological explana-
tions have begun to resemble those of IBD. Genetic factors
[161], altered enteric microbiota [164], with a variation of
additional bacterial overgrowth in the small intestine [33],
and the role of host-microbial communications are gaining
importance [6, 7, 162, 165, 213]. High production of acetate
and propionate have been observed in correlation with more
severe IBS symptoms in patients as reported by Tana et al.
[214]. Response to selective probiotics in IBS has also been
reportedalbeitwithvariablesuccess[10].Whiletheremaybe
some increased inﬂammatory cells found on histopathology
[166, 215], in cases of postinfection, there is no tissue
d e s t r u c t i o na ss e e ni nI B D .Table 3 outlines some of these
similarities.
In general, symptoms in active IBD are attributed to
inﬂammatory processes. However, a fraction of patients
deﬁned by clinical criteria to be in remission, nevertheless
suﬀer symptoms which are reminiscent of IBS and satisfy
Rome II or III criteria [216]. The use of classical anti-
inﬂammatorymedication(e.g.,corticosteroids,immunomo-
dulators, etc.) does not seem to alleviate these symptoms
and may aﬀect up to a third of patients [216]. Nonetheless,
evaluation of fecal calprotectin (a protein marker of true
inﬂammation) in such patients shows elevated levels sup-
porting the notion that these IBS-like symptoms may also be
mediated by inﬂammation. Generally, calprotectin levels are
expected to be normal in classical IBS [217].
At present, therapeutic developments targeting those
factors remain a complicated task due to the heterogeneity
within and among individuals. Unlike IBD, which has a
deﬁned immunological pathology, IBS is a highly subjective
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perceived by patients as the primary symptomatic factor
(the common ill-perceived food constituents are ones orig-
inating from dairy products, fructose and wheat products)
[167, 168, 208]. Carbohydrate ingestion, in particular, are
often avoided. There are thus two approaches to reduce the
symptoms as a result of carbohydrate ingestion. Both will be
discussed in the following.
7. Concepts of Carbohydratesand Therapy:
FODMAP WithdrawalApproach
7.1. Irritable Bowel Syndrome. After having incorporated
FODMAPs as part of their daily diet, subjects (those
with preexisting IBS, quiescent IBD condition, or free of
intestinal diseases) across several studies had all experienced
an increase in eﬄuent load, diarrhea secondary to altered
bowel/motility movements, and an overall exacerbation of
abdominal symptoms (i.e., ﬂatulence, pain, and bloating)
[169, 178]. Contrarily, results derived from other studies
involvingtherestrictionofoneormoreFODMAPfooditems
all showed an improvement of abdominal symptoms in IBS
patients [170, 218].
Twelve participants who had previously undergone
ileostomy were subjected to either a high or low FODMAP
diet for a 4-day period [178]. A 20% increase in the ileal
eﬄuent was observed after the participants consumed a high
FODMAP diet compared to low, taken into account water
content and dry weight also. The eﬄuent consistency was
reportedly thicker for the low FODMAP diet as opposed
to the high FODMAP diet. Such changes to the nature of
ileostomy output are likely inﬂuenced by the osmotically
active FODMAP components.
IsolatedfructoserestrictionforIBSpatientswithfructose
malabsorption also demonstrated a sustained improvement
of functional gut symptoms [218]. In a randomized placebo-
controlled crossover trial, fructose, fructans (these are linear
or branched polymers of fructose) and a mixture of the two
substrates were randomly reintroduced to the original low
FODMAP test diet given to a group of fructose malabsorbers
with some form of known IBS condition [169]. Despite
responding well to the low FODMAP diet for the 10-day
duration, 70% of these patients reported symptom recur-
rence (i.e., diarrhea, abdominal pain, wind, bloating, etc.)
uponhavingtheirdailymealchallengedwithfructoseand/or
fructans in a dose-dependent manner compared to only 14%
who received glucose (control). In addition, fructose and
fructan combined promoted the greatest symptom severity
than either substance alone. This study further supports the
dietaryprinciplesofFODMAPwithdrawalanddemonstrates
how eliminating the right dietary component is critical to
correct IBS symptoms.
It is postulated that the many symptoms (especially
diarrhea) felt by IBS patients may be more related to
abnormal colonic fermentation rather than osmotic eﬀects,
possibly a result of antibiotic- or gastroenteritis-induced
dysbiosis [163]. One experiment assessed such correlation
by measuring the total body excretion of hydrogen and
methane gas in a 24-hour calorimetric test [219]. A com-
parison between healthy and symptomatic IBS subjects, each
consuming two types of diet—a standard ﬁber-rich and
ﬁber-free diet—found that a signiﬁcant improvement in
abdominal symptoms is in fact associated with the reduction
of gaseous products from ﬁber-free consumption.
Ong and colleagues conducted a randomized, single-
blinded, crossover trial to evaluate the impact FODMAP
consumptionhasontheextentandspectrumofintraluminal
g a sp r o d u c t i o ni n1 5h e a l t h yv o l u n t e e r sc o m p a r e dt o1 5
IBS patients by Rome III criteria [220]. Breath hydrogen
e x c r e t i o nl ev e l sr e m a i n e df a i r l yh i ghi nb o t hgr o u p sa f t e ra2 -
day high FODMAP diet. They observed that those subjected
to a high FODMAP diet have a signiﬁcantly higher incidence
of symptoms associated with luminal extension. Interest-
ingly, those without IBS criteria also reported increase in gas
production when subjected to a high FODMAP diet, but it
did not translate to IBS-related symptoms [220]. Thus, these
results indicate that FODMAPs do not cause IBS but that
symptoms are triggered by the exaggerated bowel response
to gaseous distension [169, 220]. Another study from the UK
conﬁrmed the beneﬁt of a low FODMAP diet in IBS patients
[221]. Staudacher et al. conducted a diet questionnaire in 82
patients with IBS where they were roughly divided into equal
proportions to consume either a standard or a low FODMAP
diet. Both groups showed signiﬁcant improvements in the
overall and speciﬁc symptoms (e.g., bloating).
7.2. Inﬂammatory Bowel Disease. In the case of IBD, little
information is available concerning the speciﬁc trials involv-
ing carbohydrate restriction. The use of elemental/enteral
diets particularly in children to induce CD remission has
beenexplored,butitinvolvestherestrictionofmostelements
from reaching the lower intestine [222, 223]. A randomized
controlled trial of carbohydrate restriction was reported by
Lorenz-Meyer et al. after 15 years of study [224]. They found
somebeneﬁttopreventionofrelapseinpatientswithCD,but
intention to treat analysis failed to reach signiﬁcance. More
recently, FODMAP withdrawal was reported in a pilot study
of 72 patients (52 CD, 20 UC) over a 3-month period [225].
Out of about 70% diet-adherent patients, 50% responded
favourably with reductions in abdominal symptoms.
8. Concepts of Carbohydratesand Therapy:
Emphasis on Prebiotics
8.1. Irritable Bowel Syndrome. In contradistinction to
FODMAP withdrawal diet, regular consumption of single
or mixtures of prebiotics has also been explored for IBS in
a few studies. The concept that symptoms of carbohydrate
intolerance in healthy persons can be overcome by regular
short-term ingestion was observed in populations with
lactose intolerance [246]. A formal randomized crossover
study of lactose feeding in lactose maldigesters demonstrated
both symptomatic and fecal microﬂoral adaptation [247].
Although symptomatic improvement of lactose intolerance
may be due to a placebo eﬀect [248], changes in hydrogen
and fecal bacteria are physiological [249–251].10 International Journal of Inﬂammation
Table 4: (a) Human studies published on the use of prebiotics or nondigestible carbohydrates for inﬂammatory disorders. IBD: inﬂamma-
tory bowel disease, UC: ulcerative colitis, CD: Crohn’s disease, and P: postoperative ileoanal anastomotic pouch inﬂammation, represents a
spectrum of IBD recurrences. (b) Studies using combination of prebiotics and probiotics (synbiotics) for IBD.
(a)
Disorder N = patients Study type Active agent Outcome Reference
UC1 29 RCT Ispaghula husk Improved [226]∗
UC1 102 RCT, OL Plantago Ovata Nonsuperior [227]
UC2 10 OL GBF Improved [228]
UC2 18 OL GBF Improved [91]
UC2 21 OL GBF Improved [229]
UC2 40 RCT GBF Cytokine decreased [230]
UC1 59 RCT, OL GBF Lower recurrence [231]
UC2 19 OL OFS + IN + Bif Improved clinical endoscopy [232]
UC and CD1 20(10 controls) OL Lactulose Adaptation in UC, but not in CD [233]
UC and CD1 31 OL Lactulose No eﬀect, but improved quality of life in UC [234]
CD2 10 OL FOS, IN Improved score [235]
CD2 10 OL FOS, IN Improved [236]
CD2 103 DBRCT FOS No clinical beneﬁt, despite impacting on DC function [237]
P2 20 DBRCT IN Improved inﬂammation [238]∗
P2 21 OL Lactose Decreased bacterial sulfomucins [239]
(b)
Disorder N = patients Study type Active agent Outcome Reference
UC2 16 OL OFS + IN + Bif Improved clinical endoscopy [240]
UC1 120 RCT Bif/Psy/Bif + Psy Improved quality of life with Bif + Psy [241]
CD3 30 OL Mixed ﬁber + IN + 4 Lacto Failed to prevent relapse [242]
CD2 10 OL Psy + Bif + Lacto Clinical improvement [243]
CD2 35 DBRCT OFS + IN + Bif Clinical improvement [244]
P2 10 OL OFS, Lacto Improved and remit [245]
RCT: randomized controlled trial; DBRCT: double-blind randomized controlled trial; OL: open labeled; GBF: germinated barley foodstuﬀs; FOS: fructo-
oligosaccharides (<5 degrees of polymerization); OFS: oligofructose (5–10 degrees of polymerization); IN: inulin (<200 degrees of polymerization); Psy:





While it is well recognized that prebiotics induce symp-
toms in patients, there are now two controlled trials in
patientswithIBSwhichdemonstratedsymptomatic“adapta-
tion”toprolongedfeeding.Paineauetal.publishedadouble-
blind randomized controlled trial using short-chain fructo-
oligosaccharides in 105 patients and reported a global, yet
highly speciﬁc, symptomatic improvement by the end of the
6-week trial [252]. Similarly, trans-galacto-oligosaccharides
employed by Silk et al. in a crossover trial of 44 patients over
12 weeks also reported global and speciﬁc improvements
[253]. These two studies demonstrate that it is possible to
improve symptoms in IBS simply by providing prebiotics
on a continual basis. It is not, however, clear whether
such improvements were due to “psychological adaption” or
bacterial adaptation to carbohydrates.
8.2. Inﬂammatory Bowel Disease. Several studies examining
the possible beneﬁts of classical prebiotics (fructose or galac-
tosyl polymers) and poorly digested ﬁbers (e.g., Ispaghula
husk, germinated barley foodstuﬀs) to IBD have been
published. The rationale as outlined rests on their ability to
modulatetheintestinalmicroﬂoraandtheirbeneﬁcialconse-
quences associated with SCFAs production [91, 206]. These
studies comprised of 744 patients with UC, CD, or P (post-
operative ileoanal anastomotic pouch inﬂammation). The
variety of indications is described in Tables 4(a) and 4(b),
and includes maintenance of remission [226, 227, 231, 234],
mild to moderately active disease [91, 228–230, 232,
236–240, 244], prevention of postsurgical CD recurrence
[226, 242], and physiological assessment of adaptation capa-
bility [233]. The studies include 8 randomized controlled
trials of which 3 were double blinded [237, 238, 244]a n d
two were crossover design [226, 238]. The studies extended
from 2 weeks to 24 months (mean 4.8 ± 6.1 months, with a
median of 1.6 months). A total of 510 patients were treated
with active agent and 234 were controls. Of the controls
31 patients received probiotics without prebiotics [241].
Forty-nine treated patients were crossed over to placeboInternational Journal of Inﬂammation 11
[226, 238]. While endpoints varied, only two studies failed
to show beneﬁt. Six of the randomized studies (4 for UC
in remission [226, 227, 241] ,o n ea c t i v eC D[ 244], and one
active P [238]) showed better or nonsuperior remission rates
for UC, also improvement in clinical score for CD or P. A
small study showed reduction of proinﬂammatory cytokines
in UC [230]. However, the studies failing to show beneﬁt
included the largest and most carefully conducted DBRCT
(double-blind randomized controlled trial) of patients with
active CD [237]. Importantly, it also included the only study
albeit observational, evaluating the role of synbiotics in
CDpostsurgeryrecurrence[242].Additionalwell-conducted
trials are needed to lend clinical credence to eﬀective use of
prebiotics in IBD.
9. Summary and Conclusions
The basic premise of this paper is a conceptual contrast
of the rationale of either using a select group of prebiotic
moleculestoaltermicroﬂoraandmicrobialmetabolismorto
withhold a wide array of carbohydrates which includes those
prebiotics. The emphasis of these interventions is on use in
IBD, but IBS is used as a clinical model to outline available
but to date limited number of trials to show symptomatic
eﬃcacy. The two principles pose a scientiﬁc conundrum
particularly in IBD, while there is evidence that bacterial
immune interactions play a signiﬁcant role in IBS abnormal
immune response in IBD lead to tissue destruction.
Thereislimitedevidencethatbothapproaches(withhold
FODMAP entirely or use selective parts of FODMAP) in
IBS result in symptomatic improvement in a signiﬁcant
percentage of patients within a certain time frame. The use
of prebiotics in IBD is not settled in either active or remitting
disease. Information on the use of FODMAP or general
carbohydratewithdrawal,toourknowledge,hasbeenlimited
with IBD. The IBS-like symptoms in IBD may be related to
intestinal inﬂammation making its pathogenesis similar but
diﬀerent from that in true IBS. As such the role of beneﬁcial
bacteria and SCFAs may be more important in the former.
The real “conundrum,” then, is whether the additive
or withdrawal approach can induce microbial changes
which subsequently lead to amelioration of symptoms (as
in IBS or IBS-like symptoms in IBD), but also modula-
tion of the immune response especially inﬂammation. If
both approaches aﬀect the microﬂora, what organisms are
(equally?) modulated by a reduction in speciﬁc nutrition as
well as kept in check by other organisms like lactic acid-
producing bacteria? There is limited research on eﬀects of
withdrawal (whether total nutrient or speciﬁc nutrients like
carbohydrates). There are many publications on eﬀects of
addition of prebiotics or complex ﬁbers. The example of
NOD2 suggests that certain dietary components may be
necessary for normal function, but redundant functions are
likely. Nevertheless, until more information is available, a
judicious use of the discussed approaches and time of use
should be considered for symptom control, with withdrawal
(the less tried approach) for IBD.
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